RetroEMBRACE 研究:IB 期宫颈癌图像引导近距离放疗结果
该研究纳入 12 个中心的 123 例 FIGO1994 IB 期宫颈癌患者,接受外照射放疗(EBRT)±化疗联合图像引导近距离放疗(IGBT)。中位随访 43 个月,5 年局部控制率 98%、盆腔控制率 96%、癌症特异生存率 90%、总生存率 83%,肠道 G3–4 毒性 8%、泌尿 7%、阴道 0%。
要点
- FIGO1994 IB 期宫颈癌放化疗联合 IGBT 获得优异的局部区域控制。
- 5 年局部控制率 98%、盆腔控制率 96%、总生存率 83%。
- 晚期肠道 G3–4 毒性 8%、泌尿 7%、阴道 0%,毒性有限。
核心结论
- FIGO1994 IB 期宫颈癌接受放化疗联合 IGBT 可获得优异的局部区域控制且毒性有限。
- 在 IB 期淋巴结阴性病变中,就肿瘤学结局而言可视为等效于手术。
- 对治疗前特征不利的肿瘤,放化疗是首选,以避免手术联合辅助治疗。
研究设计与样本
- 回顾性多中心研究(RetroEMBRACE),纳入 12 个中心的 123 例 FIGO1994 IB 期宫颈癌患者。
- 患者接受外照射放疗(EBRT)±化疗联合图像引导近距离放疗(IGBT),采用 FIGO1994 分期系统。
- 计算 3 年和 5 年局部控制(LC)、盆腔控制(PC)、总生存(OS)、癌症特异生存(CSS)及晚期毒性(CTCAE v3.0)。
主要发现
- 中位年龄 48(23–82)岁;FIGO1994 IB1 占 68%、IB2 占 32%;41% 有淋巴结转移;73% 为鳞状细胞癌。
- MRI 基于的肿瘤大小 >40 mm 者占 63%;中位 EBRT 剂量 45(40–50)Gy;84% 接受化疗。
- IGBT 时 CTV-HR D90 均值 93±17 Gy(EQD2₁₀);膀胱 D2cc 76±14 Gy、直肠 66±11 Gy、乙状结肠 66±10 Gy、肠道 67±7 Gy(EQD2₃)。
- 中位随访 43 个月,9% 出现全身失败、6% 腹主动脉旁失败、3% 盆腔淋巴结失败、2% 局部失败。
- 5 年 LC 98%、PC 96%、CSS 90%、OS 83%;肠道 G3–4 毒性 8%、泌尿 7%、阴道 0%。
临床怎么用
- IB 期宫颈癌可选择放化疗联合 IGBT 作为根治性治疗,尤其适用于治疗前特征不利者。
- IB 期淋巴结阴性病变中,放化疗联合 IGBT 的肿瘤学结局可视为与手术等效。
- 对不利肿瘤,放化疗为首选,以避免手术联合辅助治疗的组合。
局限性
- 研究采用 FIGO1994 分期系统,与当前分期存在差异。
- 原文未报告研究的其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Multiple treatment options are used in early local-stage cervical cancer, including combinations of surgery with neoadjuvant/adjuvant radiotherapy and chemotherapy. Our aim was to determine the outcome for definitive chemoradiation with image guided brachytherapy (IGBT). METHODS: FIGO1994 staging system was used in our study. We included 123 patients with stage IB cervical cancer, treated at 12 centers with external beam radiotherapy (EBRT) ± Chemotherapy and IGBT. Three- and 5-year actuarial local control (LC), pelvic control (PC), overall survival (OS), cancer-specific survival (CSS) and late morbidity (CTCAE v 3.0) were computed. RESULTS: Median age was 48 (23-82) years. FIGO1994 stage distribution was: IB1 68% and IB2 32%; 41% of the entire cohort had nodal metastases and 73% squamous-cell carcinoma. MRI-based tumor size was >40 mm in 63%. Median EBRT dose was 45 (40-50) Gy; 84% received chemotherapy. At IGBT, mean CTV-HR D90 was 93 ± 17 Gy (EQD210). D2cc for bladder was 76 ± 14 Gy, rectum 66 ± 11 Gy, sigmoid 66 ± 10 Gy, bowel 67 ± 7 Gy (EQD23). At 43-months median follow-up, 9% of patients had systemic, 6% paraaortic, 3% pelvic-nodal and 2% local failure. Five-year LC was 98%, PC 96%, CSS 90%, OS 83%. Intestinal G3--4 morbidity was 8%, urinary 7% and vaginal 0%. CONCLUSIONS: Chemoradiation with IGBT for FIGO1994 stage IB cervical cancer leads to excellent loco-regional control with limited morbidity. In IB node-negative disease, it can be regarded equivalent to surgery in terms of oncologic outcome. In tumors with unfavorable pre-treatment characteristics, chemoradiation is the first choice to avoid combining surgery with adjuvant therapy.
引用
- Petric P, Lindegaard JC, Sturdza A, et al. Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study. Radiother Oncol. 2021. PMID: 33476724. doi:10.1016/j.radonc.2021.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。